The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has announced the selection of three projects to study the combination of oral decitabine (35 mg) and cedazuridine (100 mg). These projects aim to explore the potential of this medication combination in targeting tumor suppression genes. The studies, which are set to commence later in 2021, will be overseen by the NCCN ORP and funded by a grant from Taiho Oncology, who will also supply the medication.
The selected projects include:
- Michael Byrne, DO, Vanderbilt-Ingram Cancer Center, Moffitt Cancer Center: A Phase 2 Study of Decitabine and Cedazuridine in Combination with Venetoclax for AML Relapse after Allogeneic Hematopoietic Cell Transplantation.
- Gurkamal Chatta, MD, Roswell Park Comprehensive Cancer Center: A Phase 1b Clinical Trial: Improving Outcomes with Androgen Pathway inhibitors by Targeting DNA Methyltransferase Activity.
- Martin McCarter, MD, University of Colorado Cancer Center: Oral Decitabine/Cedazuridine in Combination with Nivolumab as a Strategy to Enhance the Efficacy of Immune Checkpoint Blockade in Unresectable or Metastatic Mucosal Melanoma.
Dr. Wui-Jin Koh, MD, Chief Medical Officer of NCCN, expressed enthusiasm for the potential of oral medication to improve outpatient therapy options, reduce office visits, and enhance access to care for underserved patient populations. Terri L. Washington, DNP, RN, Vice President of Scientific Partnerships and Medical Affairs Operations at Taiho Oncology, Inc., highlighted the importance of these grants in advancing critical research and exploring the full potential of oral decitabine and cedazuridine for patients.
The NCCN ORP is dedicated to fostering innovation and knowledge discovery in cancer research, supporting a wide range of projects at NCCN Member Institutions. For more information, visit NCCN.org/orp.
